Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 1, 2025
Amwell® Announces Results for First Quarter 2025
GlobeNewswire
·
May 1, 2025
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the first quarter ended March 31. Visit Amwell’s investor relations …
Synergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call Information
GlobeNewswire
·
May 1, 2025
WESTBROOK, Maine, May 01, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it plans to release financial results for the first quarter …
Sutro Biopharma to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 1, 2025
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will …
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
GlobeNewswire
·
May 1, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025. MannKind will host a …
Option Care Health to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 1, 2025
BANNOCKBURN, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will participate in the following upcoming investor …
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 1, 2025
Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 Plan to provide a proof of concept data readout in the first half of 2026 Cash of approximately $55.9 million …
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
GlobeNewswire
·
May 1, 2025
WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, will …
Streamline Health® Announces New eValuator™ Contract with Ohio-Based Health System
GlobeNewswire
·
May 1, 2025
ATLANTA, May 01, 2025 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has signed a new contract for the use of …
Stryker reports first quarter 2025 operating results
GlobeNewswire
·
May 1, 2025
Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billion Organic net sales increased 10.1% Reported operating …
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 1, 2025
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to …
Zevra Therapeutics to Participate in the Citizens Life Science Conference
GlobeNewswire
·
May 1, 2025
CELEBRATION, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that members of Zevra’s executive leadership team will participate …
Kura Oncology Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 1, 2025
– NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – …
89bio Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
May 1, 2025
– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated …
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
GlobeNewswire
·
May 1, 2025
Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity …
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
GlobeNewswire
·
May 1, 2025
- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities for BEACON-IPF trial ongoing; topline data expected in the …
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 1, 2025
Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million Company ends Q1 with $214.0 million in cash, cash equivalents …
Aura Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 1, 2025
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior …
Alignment Healthcare Reports Strong First Quarter 2025 Results; Exceeds High-End of Expectations On 4 Critical KPIs; Raises Midpoint of 2025 Guidance; Announces CFO Transition
GlobeNewswire
·
May 1, 2025
Delivers Q1 revenue of $926.9 million, up 47.5% year over year, and grows Medicare Advantage (MA) membership by 31.7% to approximately 217,500 members Exceeds high-end of Q1 guidance on membership, revenue, adjusted gross profit and adjusted EBITDA Raises …
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
GlobeNewswire
·
May 1, 2025
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, …
Ascendis Pharma Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 1, 2025
- Q1 2025 revenue of €44.7 million for YORVIPATH® and €51.3 million for SKYTROFA® - TransCon™ CNP NDA submitted in Q1 2025; MAA submission planned in Q3 2025 - Topline COACH combination trial (TransCon CNP + TransCon hGH) data expected in Q2 2025 - …